Clinical Trial Update: Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer [Phase 3]

View source ↗

Summary

Phase 3 study update evaluating olaparib plus abiraterone as first-line therapy in men with metastatic castration-resistant prostate cancer; results were posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Lynparza (olaparib)
• Zytiga (abiraterone acetate)

Snippet

Sponsor: AstraZeneca | Conditions: Metastatic Castration-resistant Prostate Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-06-15